Login / Signup

A Retrospective Budget Impact Analysis of Fidaxomicin Treatment for Clostridioides difficile Infections (CDI) in Germany.

Ann-Cathrine SiefenMelina Sophie KurteAnna Marie BauerOliver Andreas CornelySebastian M Wingen-HeimannFlorian Kron
Published in: Expert review of pharmacoeconomics & outcomes research (2024)
The analysis indicates FDX treatment can lead to cost savings compared to VAN. Future research should focus on specific patient groups, such as refractory CDI patients.
Keyphrases
  • clostridium difficile
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • prognostic factors
  • peritoneal dialysis
  • patient reported outcomes
  • replacement therapy
  • patient reported